


EUROPEAN CURRICULUM VITAE FORMAT



PERSONAL INFORMATION

Name	ORCIUOLO, ENRICO
Address	VIA MARIA MONTESSORI, 6 – 56017, SAN GIULIANO TERME (PISA) - ITALY
Telephone	(+39) 366 6609379
Certified e-mail	enrico.orciuolo.1wec@pi.omceo.it
E-mail	e.orciuolo@alumni.sssup.it e.orciuolo@ao-pisa.toscana.it
Nationality	Italian
Date of birth	13/JAN/1977

WORK EXPERIENCE

- | | |
|---|--|
| <ul style="list-style-type: none">• Dates (from – to)• Name and address of employer<ul style="list-style-type: none">• Type of business or sector• Occupation or position held• Main activities and responsibilities | <p>28/04/2020 – ongoing</p> <p>Azienda Ospedaliero Universitaria Pisana, Via Paradisa 2, 56100 Pisa - ITALY</p> <p>CAR-T Program of AOUP</p> <p>Person in charge of CAR-T program</p> <p>Coordinator of CAR-T activity in the Azienda Ospedaliero Universitaria Pisana</p> |
| <ul style="list-style-type: none">• Dates (from – to)• Name and address of employer<ul style="list-style-type: none">• Type of business or sector• Occupation or position held• Main activities and responsibilities | <p>01/10/2011 – ongoing</p> <p>Azienda Ospedaliero Universitaria Pisana, Via Paradisa 2, 56100 Pisa - ITALY</p> <p>Stem Cell Transplantation Program of AOUP</p> <p>RAQ in the adult patients section of stem cell transplantation program</p> <p>Quality control according to JACIE (Joint Accreditation Committee ISCT EBMT)</p> |
| <ul style="list-style-type: none">• Dates (from – to)• Name and address of employer<ul style="list-style-type: none">• Type of business or sector• Occupation or position held• Main activities and responsibilities | <p>24/05/2010 – ongoing</p> <p>Azienda Ospedaliero Universitaria Pisana, Via Paradisa 2, 56100 Pisa - ITALY</p> <p>Haemathology Unit</p> <p>Dirigente Medico di I Livello</p> <p>Clinical activities and stem cell transplantation activity</p> |

EDUCATION AND TRAINING

- | | |
|--|---|
| <ul style="list-style-type: none">• Dates (from – to)• Name and type of organisation providing education and training• Principal subjects/occupational skills covered• Title of qualification awarded | <p>06/04/2017 - 06/04/2027</p> <p>Ministero dell'Istruzione dell'Università e della Ricerca, Italy</p> <p>Abilitazione Scientifica Nazionale, bando D.D. 1532/2016</p> <p>Settore Concorsuale 06/D3 Malattie del Sangue, Oncologia e Reumatologia</p> <p>Abilitazione Scientifica Nazionale alle funzioni di Professore Universitario di Seconda Fascia</p> |
| <ul style="list-style-type: none">• Dates (from – to)• Name and type of organisation | <p>04/12/2021 – 31/12/2023</p> <p>American Heart Association</p> |

providing education and training

- Principal subjects/occupational skills covered
- Title of qualification awarded

- Dates (from – to)

- Name and type of organisation providing education and training

- Principal subjects/occupational skills covered

- Title of qualification awarded

- Dates (from – to)

- Name and type of organisation providing education and training

- Principal subjects/occupational skills covered

- Title of qualification awarded

- Dates (from – to)

- Name and type of organisation providing education and training

- Principal subjects/occupational skills covered

- Title of qualification awarded

- Dates (from – to)

- Name and type of organisation providing education and training

- Principal subjects/occupational skills covered

- Title of qualification awarded

- Dates (from – to)

- Name and type of organisation providing education and training

- Principal subjects/occupational skills covered

- Title of qualification awarded

- Dates (from – to)

- Name and type of organisation providing education and training

- Principal subjects/occupational skills covered

- Title of qualification awarded

ADDITIONAL PROFESSIONAL EXPERIENCES

- Dates (from – to)

- Name and type of organisation providing education and training

- Principal subjects/occupational skills covered

successfully completed the cognitive and skills evaluations in accordance with the curriculum of the American Heart Association Advanced Cardiovascular Life Support (ACLS) Program
Advanced cardiovascular life support (ACLS) provider

1/1/2006 – 31/12/2008

University of Pisa (Italy), Faculty of Biology
Department of Experimental Pathology, Medical Biotechnology, Infettivology and Epidemiology
PhD program in Microbiology and Genetics

PhD

01/10/2001 – 07/11/2005

University of Pisa (Italy), Faculty of Medicine and Surgery
School of Haematology
Residency in Haematology,

MD

01/02/2004– 31/01/2005

MD Anderson Cancer Center, University Of Texas, Houston TX, USA

Postdoctoral Fellowship in Bone Marrow Transplantation department

Postdoc

05/11/1995 – 31/10/2002

Sant'Anna School of advanced study, Pisa – Italy
Faculty of Experimental and applied sciences,
Residency in Medicine

Master's Degree in Medical Sciences

01/10/1995 – 25/07/2001

University of Pisa (Italy), Faculty of Medicine and Surgery

Medical Student

University degree in Medicine and Surgery

15/09/1990 – 15/06/1995

Liceo Scientifico Ulisse Dini, Pisa, Italy

High School student

High School degree

17/02/2021 – 19/02/2021

Humanitas University, Milano - Italy

CAR-T in DLBCL Milan Preceptorship 2021

<ul style="list-style-type: none"> • Dates (from – to) • Name and type of organisation providing education and training • Principal subjects/occupational skills covered 	<p>12/10/2010 – 14/10/2010</p> <p>Johns Hopkins University, Baltimora, MD, USA</p> <p>Advanced Course on Multiple Myeloma</p>
<ul style="list-style-type: none"> • Dates (from – to) • Name and type of organisation providing education and training • Principal subjects/occupational skills covered 	<p>06/07/2009 – 09/07/2009</p> <p>The University Of Texas, MD Anderson Cancer Center Houston TX, USA</p> <p>Advanced Course on Leukemia</p>
<ul style="list-style-type: none"> • Dates (from – to) • Name and type of organisation providing education and training • Principal subjects/occupational skills covered 	<p>04-10-2007 al 05-10-2007</p> <p>SDA Bocconi, Milano, Italy</p> <p>Corso di Formazione manageriale “La Comunicazione Scientifica in Pubblico”</p>
<ul style="list-style-type: none"> • Dates (from – to) • Name and type of organisation providing education and training • Principal subjects/occupational skills covered 	<p>12/04/2004</p> <p>The University Of Texas, MD Anderson Cancer Center Houston TX, USA</p> <p>The Safe Handling of Radioactive Materials in Research and Clinical Laboratories</p>

SELECTION OF CLINICAL STUDIES

<ul style="list-style-type: none"> • Dates (from – to) • Type of clinical study • Role in the study • Name of the study 	<p>Awaiting for Local Ethical Committee Approval</p> <p>GIMEMA CAR-T QoL</p> <p>Principal Investigator</p> <p>“Health-Related Quality of Life Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with CAR-T Cell Therapy in Real Life: A Multicenter Prospective Observational Study”.</p>
<ul style="list-style-type: none"> • Dates (from – to) • Type of clinical study • Role in the study • Name of the study 	<p>Awaiting for Local Ethical Committee Approval</p> <p>CAR-T SIE</p> <p>Principal Investigator</p> <p>A multicenter prospective observational study on Chimeric Antigen Receptor (CAR) T-cell therapy for lymphoma: monitoring feasibility, efficacy, toxicity and biomarkers in a real life setting.</p>
<ul style="list-style-type: none"> • Dates (from – to) • Type of clinical study • Role in the study • Name of the study 	<p>Awaiting for Local Ethical Committee Approval</p> <p>GIMEMA ALL2820 – EudraCT n. 2020-006048-15</p> <p>Principal Investigator</p> <p>"Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib".</p>
<ul style="list-style-type: none"> • Dates (from – to) • Type of clinical study • Role in the study • Name of the study 	<p>01/04/2022 - ongoing</p> <p>GIMEMA AML1819 – EudraCT n. 2019-003871-20</p> <p>Principal Investigator</p> <p>Phase III study to assess the impact of gemtuzumab ozogamicin, in combination with standard chemotherapy, on the levels of minimal residual disease, and the role of glasdegib as a post-transplant maintenance, in adult patients, aged 18-60 years, with previously untreated, de novo, favorable-intermediate-risk acute myeloid leukemia.</p>

<ul style="list-style-type: none"> • Dates (from – to) • Type of clinical study • Role in the study • Name of the study 	<p>24/11/2021 - ongoing</p> <p>Clinical study ATA129-EBV-205</p> <p>Principal Investigator</p> <p>An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases</p>
<ul style="list-style-type: none"> • Dates (from – to) • Type of clinical study • Role in the study • Name of the study 	<p>02/09/2020 - ongoing</p> <p>Phase I Study WP42004, Roche</p> <p>coinvestigator</p> <p>A dose escalation and expansion study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7283420</p>
<ul style="list-style-type: none"> • Dates (from – to) • Type of clinical study • Role in the study • Name of the study 	<p>15/03/2018 – ongoing</p> <p>Clinical Study SHP620-303, Shire</p> <p>coinvestigator</p> <p>Efficacy and Safety of Mirabivir in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment</p>
<ul style="list-style-type: none"> • Dates (from – to) • Type of clinical study • Role in the study • Name of the study 	<p>30/03/2017 - ongoing</p> <p>Clinical Study AC220-A-U302 QuANTUM-First, Daiichi Sankyo</p> <p>coinvestigator</p> <p>Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)</p>
<ul style="list-style-type: none"> • Dates (from – to) • Type of clinical study • Role in the study • Name of the study 	<p>16/11/2016 - 31/12/2018</p> <p>Studio GITMO LALPh+</p> <p>Principal Investigator</p> <p>Outcome del trapianto allogenico nelle leucemie acute linfoblastiche Ph positive trapiantate nei centri GITMO nel periodo 2005-2016</p>
<ul style="list-style-type: none"> • Dates (from – to) • Type of clinical study • Role in the study • Name of the study 	<p>16/05/2016 – 31/07/2020</p> <p>Clinical Study MIRROS WO29519, Roche</p> <p>coinvestigator</p> <p>A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)</p>
<ul style="list-style-type: none"> • Dates (from – to) • Type of clinical study • Role in the study • Name of the study 	<p>15/09/2009 – 15/07/2013</p> <p>Clinical Study BPO22333, Roche</p> <p>coinvestigator</p> <p>A Two Stage Phase Ib Study to Investigate the Pharmacokinetics, Safety and Tolerability of Rituximab Subcutaneous (SC) Formulation in Patients With Follicular Lymphoma (FL) as Part of Maintenance Treatment</p>
<ul style="list-style-type: none"> • Dates (from – to) • Type of clinical study • Role in the study • Name of the study 	<p>15/06/2008 – 15/06/2012</p> <p>Clinical study GAUSS BO21003 Roche</p> <p>coinvestigator</p> <p>An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma</p>
<ul style="list-style-type: none"> • Dates (from – to) • Type of clinical study • Role in the study • Name of the study 	<p>15/08/2007 – 31/12/2013</p> <p>Clinical Study ZEUS, Bayer Shering Pharma</p> <p>coinvestigator</p> <p>Phase II Study of 90Y ibritumomab tiuxetan (Zevalin®) in patients with untreated follicular non-Hodgkin's Lymphoma</p>

- Dates (from – to) 15/08/2007 - 31/12/2012
 - Type of clinical study Clinical Study MAIN B020603 Roche
 - Role in the study coinvestigator
 - Name of the study A multi-center, randomized, double-blind, placebo-controlled phase III trial comparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL)
-
- Dates (from – to) 15/10/2006 -31/12/2010
 - Type of clinical study Clinical study ML17638 Roche
 - Role in the study coinvestigator
 - Name of the study Terapia di mantenimento con rituximab versus sola osservazione dopo una breve terapia di induzione con FND-R e Rituximab, in pazienti anziani con LNH follicolare in stadio avanzato in prima linea terapeutica

MEMBER OF SCIENTIFIC SOCIETIES

- Society IMMEnSE (International Multiple Myeloma rESearch) consortium
 - Role Founder Member
 - Dates (from – to) 01/01/2011 - Ongoing
-
- Society European Society for Blood and Marrow Transplantation (EBMT)
 - Role Member
 - Dates (from – to) 01/10/2011 - ongoing
-
- Society Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare
 - Role Member
 - Dates (from – to) 01/10/2011 - ongoing

PUBLICATIONS

- 1 2022 Mazziotta F, Buda G, Del Giudice ML, **Orciuolo E**, Benedetti E, Masini M, De Tata V, Galimberti S, Petrini M. Joint Pain and Arthritis as First Clinical Manifestation of Systemic Amyloidosis and Multiple Myeloma: Case Report and Brief Literature Review. Hematol Rep. 2022 Mar 2;14(1):19-23. doi: 10.3390/hematolrep14010004.
- 2 2022 Del Principe MI, Dragonetti G, Conti A, Verga L, Ballanti S, Fanci R, Candoni A, Marchesi F, Cattaneo C, Lessi F, Fracchiolla N, Spolzino A, Prezioso L, Delia M, Potenza L, Decembrino N, Castagnola C, Nadali G, Picardi M, Zama D, **Orciuolo E**, Veggia B, Garzia M, Dargenio M, Melillo L, Manetta S, Russo D, Mancini V, Piedimonte M, Tisi MC, Toschi N, Busca A, Pagano L; behalf of the SEIFEM group; Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) group. Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey. Mycoses. 2022 Feb;65(2):171-177. doi: 10.1111/myc.13384.
- 3 2022 Canzian F, Piredda C, Macaudo A, Zawirska D, Andersen NF, Nagler A, Zaucha JM, Mazur G, Dumontet C, Wątek M, Jamrozak K, Sainz J, Várkonyi J, Butrym A, Beider K, Abildgaard N, Lesueur F, Dudziński M, Vangsted AJ, Pelosini M, Subocz E, Petrini M, Buda G, Rażny M, Gemignani F, Marques H, **Orciuolo E**, Kadar K, Jurczyszyn A, Druzd-Sitek A, Vogel U, Andersen V, Reis RM, Suska A, Avet-Loiseau H, Kruszewski M, Tomczak W, Rymko M, Minvielle S, Campa D. A polygenic risk score for multiple myeloma risk prediction. Eur J Hum Genet. 2022 Apr;30(4):474-479. doi: 10.1038/s41431-021-00986-8. Epub 2021 Nov 30.
- 4 2021 Benedetti E, Bruno B, Martini F, Morganti R, Bramanti E, Caracciolo F, Galimberti S, Lippolis P, Neri E, Arena C, Cerri F, Ricchiuto V, Pelosini M, **Orciuolo E**, Petrini M. Early Diagnosis of Neutropenic Enterocolitis by Bedside Ultrasound in Hematological Malignancies: A Prospective

Study.

J Clin Med. 2021 Sep 21;10(18):4277. doi: 10.3390/jcm10184277.

- 5 2021 Del Giudice ML, Gozzetti A, Antonioli E, **Orciuolo E**, Ghio F, Ciofini S, Candi V, Fontanelli G, Attucci I, Formica G, Bocchia M, Galimberti S, Petrini M, Buda G. Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study. *Medicina (Kaunas)*. 2021 Aug 28;57(9):900. doi: 10.3390/medicina57090900.
- 6 2021 Buda G, Del Giudice ML, Antonioli E, Ghio F, **Orciuolo E**, Morganti R, Martini F, Staderini M, Galimberti S, Petrini M. Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation. *Front Med (Lausanne)*. 2021 Aug 27;8:712070. doi: 10.3389/fmed.2021.712070. eCollection 2021.
- 7 2021 Giaccherini M, Macaudo A, **Orciuolo E**, Rymko M, Gruenpeter K, Dumontet C, Rażny M, Moreno V, Buda G, Beider K, Varkonyi J, Avet-Loiseau H, Martinez-Lopez J, Marques H, Watek M, Sarasquete ME, Andersen V, Karlin L, Suska A, Kruszewski M, Abildgaard N, Dudziński M, Butrym A, Nagler A, Vangsted AJ, Kadar K, Waldemar T, Jamroziak K, Jacobsen SEH, Ebbesen LH, Taszner M, Mazur G, Lesueur F, Pelosini M, Garcia-Sanz R, Jurczyszyn A, Demangel D, Reis RM, Iskierka-Jażdżewska E, Markiewicz M, Gemignani F, Subocz E, Zawirska D, Druzd-Sitek A, Stępień A, Alonso MH, Sainz J, Canzian F, Campa D. Genetically determined telomere length and multiple myeloma risk and outcome. *Blood Cancer J*. 2021 Apr 14;11(4):74. doi: 10.1038/s41408-021-00462-y.
- 8 2021 Del Principe MI, Buzzatti E, Piciocchi A, Forghieri F, Bonifacio M, Lessi F, Imbergamo S, **Orciuolo E**, Rossi G, Fracchiolla N, Trappolini S, Neri B, Sarlo C, Zappasodi P, Dargenio M, Cefalo M, Irno-Consalvo MA, Conti C, Paterno G, De Angelis G, Sciumè M, Della Starza I, Venditti A, Foà R, Guarini AR. Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network. *Haematologica*. 2021 Jan 1;106(1):39-45. doi: 10.3324/haematol.2019.231704.
- 9 2020 Grassi S, Guerrini F, Ciabatti E, Puccetti R, Salehzadeh S, Metelli MR, Di Vita A, Domenichini C, Caracciolo F, **Orciuolo E**, Pelosini M, Mazzantini E, Rossi P, Mazziotta F, Petrini M, Galimberti S. Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid Leukemia Patients. *Cancers (Basel)*. 2020 Jun 30;12(7):1738. doi: 10.3390/cancers12071738.
- 10 2020 Rossari F, Zucchinetti C, Buda G, **Orciuolo E**. Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications. *Cell Oncol (Dordr)*. 2020 Apr;43(2):155-176. doi: 10.1007/s13402-019-00467-7.
- 11 2019 Candoni A, Rambaldi A, Fanin R, Velardi A, Arcese W, Ciceri F, Lazzarotto D, Lussana F, Olivieri J, Grillo G, Parma M, Bruno B, Sora F, Bernasconi P, Saccardi R, Foà R, Sessa M, Bresciani P, Giglio F, Picardi A, Busca A, Sica S, Perruccio K, Zucchetti E, Diral E, Iori AP, Colombo AA, Tringali S, Santarone S, Irrera G, Mancini S, Zallio F, Malagola M, Albano F, Carella AM, Olivieri A, Tecchio C, Dominiotto A, Vacca A, Sorasio R, **Orciuolo E**, Risitano AM, Leotta S, Cortelezzi A, Mammoliti S, Oldani E, Bonifazi F; GITMO. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). *Biol Blood Marrow Transplant*. 2019 Dec;25(12):2388-2397. doi: 10.1016/j.bbmt.2019.07.037.
- 12 2019 Martini F, Buda G, De Tata V, Galimberti S, **Orciuolo E**, Masini M, Petrini M. Different types of amyloid concomitantly present in the same patients. *Hematol Rep*. 2019 Dec 4;11(4):7996. doi: 10.4081/hr.2019.7996.
- 13 2019 Salehzadeh S, Guerrini F, Pizzano U, Grassi S, Ciabatti E, Iovino L, Buda G, Caracciolo F, Benedetti E, **Orciuolo E**, Pelosini M, Consani G, Carulli G, Metelli MR, Martini F, Mazziotta F, Mazzantini E, Rossi P, Tavarozzi R, Ricci F, Petrini M, Galimberti S. The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients. *Cancer Cell Int*. 2019 Apr 4;19:83. doi: 10.1186/s12935-019-0807-0.
- 14 2019 Del Principe MI, Dragonetti G, Verga L, Candoni A, Marchesi F, Cattaneo C, Delia M, Potenza L, Farina F, Ballanti S, Decembrino N, Castagnola C, Nadali G, Fanci R, **Orciuolo E**, Veggia B, Offidani M, Melillo L, Manetta S, Tumbarello M, Venditti A, Busca A, Aversa F, Pagano L, Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group.

'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study.
J Antimicrob Chemother. 2019 Apr 1;74(4):1062-1068. doi: 10.1093/jac/dky550.

- 15 2019 Iovino L, Mazziotta F, Buda G, **Orciuolo E**, Caracciolo F, Pelosini M, Morganti R, Galimberti S, Benedetti E, Petrini M. The Onset of Monoclonal and Oligoclonal Gammopathies Is a Good Prognostic Factor after Allogeneic Stem Cell Transplantation.
Acta Haematol. 2019;141(1):7-11. doi: 10.1159/000493416.
- 16 2018 Rossari F, Minutolo F, **Orciuolo E**.
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.
J Hematol Oncol. 2018 Jun 20;11(1):84. doi: 10.1186/s13045-018-0624-2.
- 17 2018 Olivieri J, Mosna F, Pelosini M, Fama A, Rattotti S, Giannoccaro M, Carli G, Tisi MC, Ferrero S, Sgherza N, Mazzone AM, Marino D, Calimeri T, Loseto G, Saraceni F, Tomei G, Sica S, Perali G, Codeluppi K, Billio A, Olivieri A, **Orciuolo E**, Matera R, Stefani PM, Borghero C, Ghione P, Cascavilla N, Lanza F, Chiusolo P, Finotto S, Federici I, Gherlinzoni F, Centurioni R, Fanin R, Zaja F; Fondazione Italiana Linfomi Postgraduate Master Course.
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Biol Blood Marrow Transplant. 2018 Sep;24(9):1814-1822. doi: 10.1016/j.bbmt.2018.05.018.
- 18 2018 Iovino L, Mazziotta F, Carulli G, Guerrini F, Morganti R, Mazzotti V, Maggi F, Macera L, **Orciuolo E**, Buda G, Benedetti E, Caracciolo F, Galimberti S, Pistello M, Petrini M.
High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naïve lymphocytes and prevents TTV reactivation.
Leuk Res. 2018 Jul;70:20-24. doi: 10.1016/j.leukres.2018.04.016.
- 19 2018 Cattaneo C, Di Blasi R, Skert C, Candoni A, Martino B, Di Renzo N, Delia M, Ballanti S, Marchesi F, Mancini V, **Orciuolo E**, Cesaro S, Prezioso L, Fanci R, Nadali G, Chierichini A, Facchini L, Picardi M, Malagola M, Orlando V, Trecarichi EM, Tumbarello M, Aversa F, Rossi G, Pagano L; SEIFEM Group.
Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria.
Ann Hematol. 2018 Sep;97(9):1717-1726. doi: 10.1007/s00277-018-3341-6.
- 20 2018 Martini F, Buda G, **Orciuolo E**, Galimberti S, Mazziotta F, Petrini M.
Plasma Cell Disorders and Dialysis-Dependent Renal Failure: Safety and Efficacy of Autologous Stem Cell Transplantation.
Acta Haematol. 2018 Feb 7;139(2):101-103. doi: 10.1159/000486359.
- 21 2017 Buda G, Guerrini F, Galimberti S, **Orciuolo E**, Pacini S, Mazzantini E, Petrini M.
PRDI-BF1 and PRDI-BF1P isoform expressions correlate with disease status in multiple myeloma patients.
Hematol Rep. 2017 Dec 22;9(4):7201. doi: 10.4081/hr.2017.7201.
- 22 2016 Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, **Orciuolo E**, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A.
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Br J Haematol. 2016 Jan;172(1):111-21. doi: 10.1111/bjh.13803.
- 23 2016 Ríos-Tamayo R, Lupiañez CB, Campa D, Hielscher T, Weinhold N, Martínez-López J, Jerez A, Landi S, Jamroziak K, Dumontet C, Wątek M, Lesueur F, Reis RM, Marques H, Jureczyszyn A, Vogel U, Buda G, García-Sanz R, **Orciuolo E**, Petrini M, Vangsted AJ, Gemignani F, Försti A, Goldschmidt H, Hemminki K, Canzian F, Jurado M, Sainz J.
A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMESE consortium and meta-analysis.
Oncotarget. 2016 Sep 13;7(37):59029-59048. doi: 10.18632/oncotarget.10665.
- 24 2015 Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jureczyszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, García-Sanz R, Buda G, Gemignani F, Ríos R, Vangsted AJ, Dumontet C, Martínez-López J, Moreno MJ, Stępień A, Wątek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SE, Goldschmidt H, Sainz J, Hillengass J, **Orciuolo E**, Dudziński M, Weinhold N, Reis RM, Canzian F.
Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.
Int J Cancer. 2015 Mar 1;136(5):E351-8. doi: 10.1002/ijc.29101.
- 25 2015 Ríos R, Lupiañez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi J, García-Sanz R,

Jamroziak K, Dumontet C, Cayuela AJ, Wętek M, Landi S, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczyszyn A, Andersen V, Vogel U, Buda G, **Orciuolo E**, Jacobsen SE, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J.

Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium.

Endocr Relat Cancer. 2015 Aug;22(4):545-59. doi: 10.1530/ERC-15-0029.

- 26 2014 Fontanelli G, Rocco M, Caracciolo F, Benedetti E, Buda G, **Orciuolo E**, Carulli G, Galimberti S, Azzarà A, Petrini M. Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):e13-7. doi: 10.1016/j.clml.2013.08.005.
- 27 2014 Martino A, Campa D, Jurczyszyn A, Martínez-López J, Moreno MJ, Varkonyi J, Dumontet C, García-Sanz R, Gemignani F, Jamroziak K, Stępieł A, Jacobsen SE, Andersen V, Jurado M, Landi S, Rossi AM, Lesueur F, Marques H, Dudziński M, Wętek M, Moreno V, **Orciuolo E**, Petrini M, Reis RM, Ríos R, Sainz J, Vogel U, Buda G, Vangsted AJ, Canzian F. Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era. Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):670-4. doi: 10.1158/1055-9965.
- 28 2014 Ibatici A, Pica GM, Nati S, Vitolo U, Botto B, Ciochetto C, Petrini M, Galimberti S, Ciabatti E, **Orciuolo E**, Zinzani PL, Cascavilla N, Guolo F, Fraternali Orcioni G, Carella AM. Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Br J Haematol. 2014 Mar;164(5):710-6. doi: 10.1111/bjh.12695.
- 29 2013 Buda G, **Orciuolo E**, Carulli G, Galimberti S, Ghio F, Cervetti G, Pelosini M, Petrini M. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients. Acta Haematol. 2013;129(1):35-9. doi: 10.1159/000339635.
- 30 2013 Martino A., Campa D., Buda G., Sainz J., García-Sanz R., Jamroziak K., Reis R.M., Weinhold N., Jurado M., Ríos R., Szemraj-Rogucka Z., Marques H., Szemraj J., Stein A., Kumar R., **Orciuolo E.**, Gemignani F., Landi S., Goldschmidt H., Petrini M., Dumontet C., Canzian F., Rossi A.M. Erratum: Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: A case - Control study in the context of the international Multiple Myeloma rESEarch (IMMEnSE) consortium. (Leukemia (2012) 26 (1419-1422) DOI: 10.1038/leu.2011.352). Leukemia (2013), vol. 27, p. 1615-1616, ISSN: 0887-6924
- 31 2012 Rigacci L, Puccini B, Cortelazzo S, Gaidano G, Piccin A, D'Arco A, Freilone R, Storti S, **Orciuolo E**, Zinzani PL, Zaja F, Bongarzone V, Balzarotti M, Rota-Scalabrini D, Patti C, Gobbi M, Carpaneto A, Liberati AM, Bosi A, Iannitto E. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann Hematol. 2012 Jul;91(7):1013-22. doi: 10.1007/s00277-012-1422-5.
- 32 2012 Campa D, Martino A, Sainz J, Buda G, Jamroziak K, Weinhold N, Vieira Reis RM, García-Sanz R, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Lesueur F, Bugert P, Moreno V, Szemraj J, **Orciuolo E**, Gemignani F, Rossi AM, Dumontet C, Petrini M, Goldschmidt H, Landi S, Canzian F. Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. Br J Haematol. 2012 May;157(3):331-8.
- 33 2012 Martino A, Sainz J, Buda G, Jamroziak K, Reis RM, García-Sanz R, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Lesueur F, Moreno V, **Orciuolo E**, Gemignani F, Landi S, Rossi AM, Dumontet C, Petrini M, Campa D, Canzian F. Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). Int J Oncol. 2012 Mar;40(3):625-38. doi: 10.3892/ijo.2011.1284.
- 34 2012 Martino A, Campa D, Buda G, Sainz J, García-Sanz R, Jamroziak K, Reis RM, Weinhold N, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Szemraj J, Stein A, Kumar R, **Orciuolo E**, Gemignani F, Landi S, Goldschmidt H, Petrini M, Dumontet C, Canzian F, Rossi AM. Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. Leukemia. 2012 Jun;26(6):1419-22. doi: 10.1038/leu.2011.352.
- 35 2012 Martino A, Campa D, Jamroziak K, Reis RM, Sainz J, Buda G, García-Sanz R, Lesueur F, Marques H, Moreno V,

Jurado M, Ríos R, Szemraj-Rogucka Z, Szemraj J, Tjønneland A, Overvad K, Vangsted AJ, Vogel U, Mikala G, Kádár K, Szombath G, Varkonyi J, **Orciuolo E**, Dumontet C, Gemignani F, Rossi AM, Landi S, Petrini M, Houlston RS, Hemminki K, Canzian F.

Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma.

Br J Haematol. 2012 Sep;158(6):805-9. doi: 10.1111/j.1365-2141.2012.09244.x.

- 36 2012 Erba PA, Sollini M, **Orciuolo E**, Traino C, Petrini M, Paganelli G, Bombardieri E, Grana C, Giovannoni L, Neri D, Menssen HD, Mariani G.
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies.
J Nucl Med. 2012 Jun;53(6):922-7. doi: 10.2967/jnumed.111.101006.
- 37 2012 Martino A, Buda G, Maggini V, Lapi F, Lupia A, Di Bello D, **Orciuolo E**, Galimberti S, Barale R, Petrini M, Rossi AM.
Could age modify the effect of genetic variants in IL6 and TNF- α genes in multiple myeloma?
Leuk Res. 2012 May;36(5):594-7. doi: 10.1016/j.leukres.2012.02.009.
- 38 2011 **Orciuolo E**, Buda G, Marturano E, Mauro E, Milone G, Cangialosi C, Di Renzo N, Pastore D, Specchia G, De Paolis MR, Mazza P, Pietrantonio G, Petrini M.
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization.
Leuk Res. 2011 Jul;35(7):899-903. doi: 10.1016/j.leukres.2010.10.029.
- 39 2011 Buda G, **Orciuolo E**, Galimberti S, Pelosini M, Petrini M.
Erratum: Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients (Annals Hematology 2011 doi: 10.1007/s00277-010-1136-5).
Ann Hematol. 2011 Jul;90(7):863.
- 40 2011 Buda G, **Orciuolo E**, Galimberti S, Pelosini M, Petrini M.
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Ann Hematol. 2011 Sep;90(9):1115-6. doi: 10.1007/s00277-010-1136-5.
- 41 2010 **Orciuolo E**, Buda G, Sordi E, Baraté C, Galimberti S, Cancia E, Petrini M.
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma.
Leuk Res. 2010 Feb;34(2):184-9. doi: 10.1016/j.leukres.2009.04.003.
- 42 2010 Buda G, Carulli G, **Orciuolo E**, Cannizzo E, Pelosini M, Galimberti S, Petrini M.
CD23 expression in plasma cell leukaemia.
Br J Haematol. 2010 Sep;150(6):724-5. doi: 10.1111/j.1365-2141.2010.08277.x.
- 43 2010 Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias (Leone G, Voso MT, D'Arco AM, Tatarelli C, Ferrero D, Gaidano G, Palumbo G, Di Raimondo F, Oliva E, Sanpaolo G, Tonso A, Santagostino A, Filardi N, Candoni A, Fili C, Russo D, **Orciuolo E**, Petrini M, Ciuffreda L, Riezzo A, Morabito F, Mazza P, Pastore D, Specchia G.).
Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program.
Cancer. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894.
- 44 2010 Carulli G, **Orciuolo E**, Cannizzo E, Bianchi G, Giuntini S, Ottaviano V, Galimberti S, Marini A, Buda G, Ghimenti M, Petrini M.
Combination of morphology, flow cytometry and PCR assay to detect bone marrow infiltration in B-cell non-Hodgkin's lymphomas.
Clin Ter. 2010;161(3):253-8.
- 45 2010 Galimberti S, Nagy B, Palumbo GA, Cancia E, Buda G, **Orciuolo E**, Melosi A, Lambelet P, Ronca F, Petrini M.
Vascular endothelial growth factor polymorphisms in mantle cell lymphoma.
Acta Haematol. 2010;123(2):91-5. doi: 10.1159/000267826.
- 46 2010 **Orciuolo E**, Buda G, Pelosini M, Petrini M.
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
Br J Haematol. 2010 Mar;148(5):810-2. doi: 10.1111/j.1365-2141.2009.07998.x.
- 47 2010 Cervetti G, Galimberti S, Sordi E, Buda G, **Orciuolo E**, Cecconi N, Petrini M.
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).
Ann Oncol. 2010 Apr;21(4):851-4. doi: 10.1093/annonc/mdp395.

- 48 2009 Cannizzo E, Carulli G, Buda G, Zucca A, Azzarà A, **Orciuolo E**, Petrini M.
Meningeal relapse in a case of B acute lymphoblastic leukemia: the role of CD56 expression.
Med Sci Monit. 2009 Feb;15(2):CS27-29.
- 49 2009 Buda G, Martino A, Maggini V, **Orciuolo E**, Galimberti S, Gentile M, Morabito F, Antognoni F, Brunori M, Barale R, Rossi AM, Petrini M.
MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma.
Acta Haematol. 2009;122(1):42-5. doi: 10.1159/000235820.
- 50 2009 Lorenzoni A., Boni G., Mazzarri S., Cecconi N., **Orciuolo E.**, Petrini M., Mariani G., De Negri F.
Radioimmunotherapy of indolent non Hodgkin's lymphoma: Evaluation of long-term responses in patients treated with 90Y-ibritumomab tiuxetan.
Giornale Italiano di Allergologia e Immunologia Clinica, vol 19, p.167-170, ISSN:1120-6373
- 51 2009 Buda G, **Orciuolo E**, Galimberti S, Cecconi N, Petrini M.
Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma.
Acta Haematol. 2009;122(1):39-41. doi: 10.1159/000235819.
- 52 2008 Galimberti S, Canestraro M, Khan R, Buda G, **Orciuolo E**, Guerrini F, Fazzi R, Maffei R, Marasca R, Petrini M.
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines.
Leukemia. 2008 Mar;22(3):628-31.
- 53 2008 Trombi L, Mattii L, Pacini S, D'Alessandro D, Battolla B, **Orciuolo E**, Buda G, Fazzi R, Galimberti S, Petrini M.
Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing.
J Orthop Res. 2008 Feb;26(2):176-83.
- 54 2008 Buda G, **Orciuolo E**, Maggini V, Galimberti S, Barale R, Rossi AM, Petrini M.
Other mechanisms to explain the role of reduced folate carrier in cancer.
Eur J Haematol. 2008 Apr;80(4):365. doi: 10.1111/j.1600-0609.2008.01028.x.
- 55 2008 Buda G, **Orciuolo E**, Maggini V, Galimberti S, Barale R, Rossi AM, Petrini M.
MDR1 pump: more than a drug transporter comment on "Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukaemia" by Hattori et al. [Leuk. Res. (in press)].
Leuk Res. 2008 Feb;32(2):359-60.
- 56 2008 Maggini V, Buda G, Galimberti S, Martino A, **Orciuolo E**, Morabito F, Bono R, Barale R, Petrini M, Rossi AM.
Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk.
Leuk Res. 2008 Jun;32(6):988-90.
- 57 2008 Buda G, **Orciuolo E**, Galimberti S, Petrini M, Maggini V, Barale R, Rossi AM.
Unusual association of endometrial cancer and multiple myeloma.
Gynecol Oncol. 2008 Aug;110(2):265-6
- 58 2008 Focosi D, Cecconi N, Boni G, **Orciuolo E**, Galimberti S, Petrini M.
Acute myeloid leukaemia after treatment with (90)Y-ibritumomab tiuxetan for follicular lymphoma.
Hematol Oncol. 2008 Sep;26(3):179-81. doi: 10.1002/hon.849.
- 59 2008 Buda G, **Orciuolo E**, Maggini V, Galimberti S, Barale R, Rossi AM, Petrini M.
MDR1 modulates apoptosis in CD34+ leukemic cells.
Ann Hematol. 2008 Dec;87(12):1017-8. doi: 10.1007/s00277-008-0515-7.
- 60 2008 Carulli G, Cannizzo E, Zucca A, Buda G, **Orciuolo E**, Marini A, Petrini M.
CD45 expression in low-grade B-cell non-Hodgkin's lymphomas.
Leuk Res. 2008 Feb;32(2):263-7.
- 61 2008 Galimberti S, Canestraro M, Pacini S, Fazzi R, **Orciuolo E**, Trombi L, Mattii L, Battolla B, Capodanno A, Collecchi P, Veroni F, Simi P, Piaggi S, Casini A, Petrini M.
PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells.
Leuk Res. 2008 Jan;32(1):103-12.
- 62 2008 Cervetti G, Carulli G, Galimberti S, Azzarà A, Buda G, **Orciuolo E**, Pelosini M, Petrini M.
Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia.

- 63 2008 **Orciuolo E**, Buda G, Galimberti S, Cervetti G, Cecconi N, Papineschi F, Petrini M.
Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy resistance index in chronic myeloid leukaemia.
Leuk Res. 2008 Jan;32(1):190-1.
- 64 2008 Cervetti G, Carulli G, Galimberti S, Azzarà A, Cannizzo E, Buda G, **Orciuolo E**, Petrini M.
Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia.
Leuk Res. 2008 Jan;32(1):191-2.
- 65 2008 Buda G, **Orciuolo E**, Galimberti S, Benedetti E, Caracciolo F, Cervetti G, Carulli G, Papineschi F, Petrini M.
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia.
Leuk Res. 2008 Jan;32(1):192-4.
- 66 2008 **Orciuolo E**, Buda G, Galimberti S, Cecconi N, Cervetti G, Petrini M.
Concomitant translocation t(14;22)(q32;q11) in a case of chronic myeloid leukemia.
Leuk Res. 2008 Jan;32(1):188-90.
- 67 2008 Maggini V, Buda G, Martino A, Presciuttini S, Galimberti S, **Orciuolo E**, Barale R, Petrini M, Rossi AM.
MDR1 diplotypes as prognostic markers in multiple myeloma.
Pharmacogenet Genomics. 2008 May;18(5):383-9. doi: 10.1097/FPC.0b013e3282f82297.
- 68 2008 Gennai A, Basili G, Lorenzetti L, Crocetti G, Filidei M, **Orciuolo E**, Prosperi V, Goletti O.
Spontaneous rupture of the spleen in non-hodgkin lymphoma: a case report.
Chir Ital. 2008 Sep-Oct;60(5):739-44.
- 69 2008 Buda G, **Orciuolo E**, Maggini V, Petrini M.
Folic acid fortification and cancer risk.
Lancet. 2008 Apr 19;371(9621):1336. doi: 10.1016/S0140-6736(08)60592-9.
- 70 2007 Buda G, **Orciuolo E**, Galimberti S, Carulli G, Petrini M.
Association of PIM gene translocation and TEL/AML1 rearrangement.
Leuk Res. 2007 Dec;31(12):1761-2.
- 71 2007 Buda G, Galimberti S, **Orciuolo E**, Caracciolo F, Cecconi N, Gasparini M, Petrini M.
Stable low IgG levels in relapsed non-Hodgkin's lymphomas.
Ann Hematol. 2007 Nov;86(11):851-3.
- 72 2007 Buda G, Carulli G, **Orciuolo E**, Cannizzo E, Zucca A, Azzarà A, Rossi A, Galimberti S, Cecconi N, Petrini M.
Two cases of plasma cell leukemia with atypical immunophenotype.
Acta Haematol. 2007;118(1):27-9.
- 73 2007 Piaggi S, Novelli M, Martino L, Masini M, Raggi C, **Orciuolo E**, Masiello P, Casini A, De Tata V.
Cell death and impairment of glucose-stimulated insulin secretion induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the beta-cell line INS-1E.
Toxicol Appl Pharmacol. 2007 May 1;220(3):333-40.
- 74 2007 Buda G, **Orciuolo E**, Cecconi N, Galimberti S, Cervetti G, Petrini M.
Poor prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation, t(9;10;22)(q34;q24;q11).
Leuk Res. 2007 Dec;31(12):1765-6.
- 75 2007 **Orciuolo E**, Buda G, Galimberti S, Cecconi N, Versari D, Salvetti A, Petrini M.
Unexpected cardiotoxicity in haematological bortezomib treated patients.
Br J Haematol. 2007 Aug;138(3):396-7. DOI: 10.1111/j.1365-2141.2007.06659.x
- 76 2007 **Orciuolo E**, Buda G, Galimberti S, Sordi E, Cervetti G, Petrini M.
Concomitant appearance of trisomy 8 and isochromosome 17q in a Philadelphia-positive clone in a patient with chronic myeloid leukemia in chronic phase: an alarm for changing therapeutic strategy.
Cancer Genet Cytogenet. 2007 Sep;177(2):166-7.
- 77 2007 **Orciuolo E**, Cecconi N, Galimberti S, Papineschi F, Petrini M.
Match unrelated bone marrow transplantation in a case of high risk myelodysplastic syndrome treated with azacitidine and concomitant 1alpha-25-dihydroxyvitamin D3, as differentiating agent.
Leuk Res. 2007 Sep;31(9):1321-3.

- 78 2007 **Orciuolo E**, Stanzani M, Canestraro M, Galimberti S, Carulli G, Lewis R, Petrini M, Komanduri KV.
Effects of *Aspergillus fumigatus* gliotoxin and methylprednisolone on human neutrophils: implications for the pathogenesis of invasive aspergillosis.
J Leukoc Biol. 2007 Oct;82(4):839-48.
- 79 2007 Fazzi R, **Orciuolo E**, Trombi L, Mattii L, Battola B, Riccioni R, Carulli G, Galimberti S, Petrini M.
PEG-Filgrastim activity on granulocyte functions.
Leuk Res. 2007 Oct;31(10):1453-5.
- 80 2007 **Orciuolo E**, Galimberti S, Petrini M.
Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitro.
Leuk Res. 2007 Jul;31(7):1026-7.
- 81 2007 **Orciuolo E**, Buda G, Cecconi N, Galimberti S, Petrini M.
A therapy resistant myelodysplastic syndrome characterized by the presence of the rare reciprocal translocation t(3;12)(q26.2;p13).
Leuk Res. 2007 Nov;31(11):1599-600.
- 82 2006 **Orciuolo E**, Fazzi R, Galimberti S, Testi C, Azzara' A, Carulli G, Petrini M.
Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy.
Leuk Res. 2006 Mar;30(3):349-53.
- 83 2005 Stanzani M, **Orciuolo E**, Lewis R, Kontoyiannis DP, Martins SL, St John LS, Komanduri KV.
Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes.
Blood. 2005 Mar 15;105(6):2258-65.
- 84 2004 Fazzi R, Galimberti S, Pacini S, Testi R, Azzarà A, **Orciuolo E**, Trombi L, Metelli MR, Petrini M.
Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide III. Action on human megakaryocytopoiesis: focus on essential thrombocythemia.
Leuk Res. 2004 Oct;28(10):1097-105.
- 85 2004 **Orciuolo E**, Azzarà A, Bandini G, Galimberti S, Bonifazi F, Fazzi R, Petrini M.
Contemporaneous appearance, 18 years after allogeneic bone marrow transplantation, of myelodysplastic syndrome in the patient and the donor.
Bone Marrow Transplant. 2004 Apr;33(8):859-61.

PARTECIPAZIONE COME

RELATORE A CORSI E CONVEGNI

(SELEZIONE IN BASE ALLA DISPONIBILITÀ DI DOCUMENTAZIONE PROVANTE)

Convegno	"CAR-ToMEET Project", area Toscana
Ruolo	Relatore
Sede e data	Webinar, 22/04/2021
Convegno	"Prospettive attuali o future all'uso delle CAR-T in Italia"
Ruolo	Relatore
Sede e data	Firenze, 18-06-2019
Convegno	"La Leucemia Acuta Promielocitica: recenti acquisizioni sulla patogenesi, diagnosi e terapia"
Ruolo	Relatore
Sede e data	Pisa, 07-06-2016
Corso	"La gestione dei pazienti con linfoma non Hodgkin e leucemia linfatica cronica: corso teorico-pratico"
Ruolo	Docente
Sede e data	Pisa, 02-04 Aprile 2014

Convegno	"I Linfomi"
Ruolo	Relatore
Sede e data	Pistoia, 13-10-2012
Convegno	"Implicazioni clinico-biologiche nell'uso delle cellule staminali"
Ruolo	Relatore
Sede e data	Pisa, 10-11 Febbraio 2012
Convegno	VII Congresso Nazionale della Società Medica Interdisciplinare
Ruolo	Relatore
Sede e data	Pisa, 1-3 Dicembre 2011
Convegno	"Linfomi: Hot Spots"
Ruolo	Relatore
Sede e data	Vallombrosa (FI), 23-09-2011
Convegno	Associazione Schirinzi A. Mario e International Myeloma Foundation
Ruolo	Relatore
Sede e data	Pisa, 12-09-2010
Convegno	14th Congress of the European Hematology Association
Ruolo	Oral presentation "Incidence of febrile episodes during stem cell mobilization after high dose cyclophosphamide chemotherapy and G-CSF (filgrastim or lenograstim) administration in multiple myeloma patients: study update"
Sede e data	Berlino, 4-7 Giugno 2009
Corso	"Diagnosi e Terapia dei Linfomi"
Ruolo	Docente
Sede e data	Pisa, 27-29 Novembre 2008
Convegno	"Linfomi indolenti non follicolari, focus nella gestione del paziente ansiano"
Ruolo	Relatore
Sede e data	Pisa, 24-10-2008
Advisory Board	"Nuovi sviluppi nel NHL: quali approcci terapeutici post ASH?"
Ruolo	Relatore
Sede e data	Milano, 25-02-2008
Corso	"Le terapie di supporto in oncoematologia"
Ruolo	Docente
Sede e data	Pisa, 04-12-2007
Convegno	"Tavola rotonda trombocitemia essenziale: casi clinici e opzioni terapeutiche"
Ruolo	Relatore
Sede e data	Pisa, 10-07-2007

PERSONAL SKILLS AND COMPETENCES

NATIVE LANGUAGE **ITALIAN**

OTHER LANGUAGES

Livello Europeo ()*

English

Spanish

German

Comprehension				Verbal skills				Writing skills	
Listening		Reading		Dialogue		Presentation			
C1	Excellent	C1	Excellent	C1	Excellent	C1	Excellent	C1	Excellent
B1	Good	B1	Good	B1	Good	B1	Good	A2	Basic
A2	Basic	A2	Basic	A2	Basic	A2	Basic	A2	Poor

(*) [Common European Framework of Reference for Languages](#)

Language Certifications

English

Certificate of Advanced English (2002)

Spanish

Language exam at Scuola Superiore S. Anna. Pisa (2001)

German

Language exam at Scuola Superiore S. Anna. Pisa (1998)

ATTIVITÀ DIDATTICA

Lezioni di ADO (Attività didattica opzionale) per il corso di Medicina e Chirurgia dell'Università degli Studi di Pisa.

Tutor della Scuola di Specializzazione di Ematologia della Università degli studi di Pisa.

Correlatore di tesi di Laurea in Medicina e Chirurgia e Igiene Dentale presso l'Università di Pisa.

Tutor presso la UO Ematologia dell'Azienda Ospedaliero Universitaria Pisana degli Studenti durante il tirocinio obbligatorio e facoltativo.

Pisa, 18 Aprile 2022

Il Dichiarante

Enrico Orciuolo

